Market Cap 101.37M
Revenue (ttm) 180,000.00
Net Income (ttm) -9.54M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -5,300.00%
Debt to Equity Ratio 0.00
Volume 171,812
Avg Vol 152,396
Day's Range N/A - N/A
Shares Out 45.66M
Stochastic %K 51%
Beta 1.68
Analysts Sell
Price Target $10.00

Company Profile

Entera Bio Ltd., a clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs. The company leverages its N-Tab platform that is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream. It also develops EB613, an oral PTH (1-34), that has completed Phase 2 clinical trial for the treatment of post-menopausal women with low bone mineral density and high-risk osteoporosis;...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 2 532 7151
Address:
Kiryat Hadassah Minrav Building, Fifth Floor, Jerusalem, Israel
Nader5444
Nader5444 Oct. 28 at 6:32 PM
0 · Reply
Stringy51
Stringy51 Oct. 28 at 2:52 PM
$ENTX https://www.linkedin.com/posts/pharmaverse-podcast_leadership-hiringtips-womeninleadership-activity-7378803474962063361-Tjx9?utm_medium=ios_app&rcm=ACoAAAr1XmMBPzloCRFlzmT6eeMwfl0wN-JDgu0&utm_source=social_share_send&utm_campaign=copy_link Interesting interview done recently. Hopefully that with good research we can keep this heading the right direction.
0 · Reply
Nader5444
Nader5444 Oct. 27 at 9:21 PM
0 · Reply
tymtested
tymtested Oct. 24 at 9:49 PM
$ENTX market only buys potential if its AI
0 · Reply
WallStWireAds
WallStWireAds Oct. 24 at 8:51 AM
0 · Reply
InfinityAndBeyond_
InfinityAndBeyond_ Oct. 24 at 2:38 AM
0 · Reply
MissionParabolica
MissionParabolica Oct. 23 at 4:36 PM
Ticker GIPR gearing up for a massive run🚨🚨 This low float undervalued gem is starting to grind up, can see 200-400%+ run is a wild market like this. GIPR 💎Rev up $5.4M → $7.6M 💎73% gross margin 💎Best Buy lease extended 💎No dilution. 💎If treasury or merger news hits this is gone! $BYND $IBIO $ENTX $SILO 8
0 · Reply
_www_larval_com_
_www_larval_com_ Oct. 23 at 3:07 PM
$ENTX just reversed 3% higher to -1% (~2Mv) a moment ago, 11/21 options, follow for more volatility.
0 · Reply
Butcher1871
Butcher1871 Oct. 23 at 2:30 PM
$ENTX thought this might move after hearing the news, whats the deal with this stock then long term holders?
2 · Reply
DARKP00L
DARKP00L Oct. 23 at 1:34 PM
$ENTX 09:05 on Oct. 23 2025 Entera Bio Presents New Clinical Data From Phase 2 Study Of EB613 At 2025 North American Menopause Society Annual Meeting; Intends To Initiate Global Registrational Phase 3 Trial After July 2025 FDA Concurrence #tradeideas
0 · Reply
Latest News on ENTX
Entera Bio to Participate in Upcoming Events

Feb 24, 2025, 8:30 AM EST - 8 months ago

Entera Bio to Participate in Upcoming Events


Entera Bio to Participate in Upcoming Investor Conferences

Sep 5, 2023, 8:00 AM EDT - 2 years ago

Entera Bio to Participate in Upcoming Investor Conferences


Entera Bio Regains Compliance with Nasdaq Listing Requirements

Mar 23, 2023, 9:27 AM EDT - 2 years ago

Entera Bio Regains Compliance with Nasdaq Listing Requirements


Entera Bio Outlines Pivotal Osteoporosis Trial, Names New CEO

Jul 18, 2022, 9:23 AM EDT - 3 years ago

Entera Bio Outlines Pivotal Osteoporosis Trial, Names New CEO


Nader5444
Nader5444 Oct. 28 at 6:32 PM
0 · Reply
Stringy51
Stringy51 Oct. 28 at 2:52 PM
$ENTX https://www.linkedin.com/posts/pharmaverse-podcast_leadership-hiringtips-womeninleadership-activity-7378803474962063361-Tjx9?utm_medium=ios_app&rcm=ACoAAAr1XmMBPzloCRFlzmT6eeMwfl0wN-JDgu0&utm_source=social_share_send&utm_campaign=copy_link Interesting interview done recently. Hopefully that with good research we can keep this heading the right direction.
0 · Reply
Nader5444
Nader5444 Oct. 27 at 9:21 PM
0 · Reply
tymtested
tymtested Oct. 24 at 9:49 PM
$ENTX market only buys potential if its AI
0 · Reply
WallStWireAds
WallStWireAds Oct. 24 at 8:51 AM
0 · Reply
InfinityAndBeyond_
InfinityAndBeyond_ Oct. 24 at 2:38 AM
0 · Reply
MissionParabolica
MissionParabolica Oct. 23 at 4:36 PM
Ticker GIPR gearing up for a massive run🚨🚨 This low float undervalued gem is starting to grind up, can see 200-400%+ run is a wild market like this. GIPR 💎Rev up $5.4M → $7.6M 💎73% gross margin 💎Best Buy lease extended 💎No dilution. 💎If treasury or merger news hits this is gone! $BYND $IBIO $ENTX $SILO 8
0 · Reply
_www_larval_com_
_www_larval_com_ Oct. 23 at 3:07 PM
$ENTX just reversed 3% higher to -1% (~2Mv) a moment ago, 11/21 options, follow for more volatility.
0 · Reply
Butcher1871
Butcher1871 Oct. 23 at 2:30 PM
$ENTX thought this might move after hearing the news, whats the deal with this stock then long term holders?
2 · Reply
DARKP00L
DARKP00L Oct. 23 at 1:34 PM
$ENTX 09:05 on Oct. 23 2025 Entera Bio Presents New Clinical Data From Phase 2 Study Of EB613 At 2025 North American Menopause Society Annual Meeting; Intends To Initiate Global Registrational Phase 3 Trial After July 2025 FDA Concurrence #tradeideas
0 · Reply
signaljumper
signaljumper Oct. 23 at 1:21 PM
$ENTX Grear News from Phase 2 https://www.globenewswire.com/news-release/2025/10/23/3172057/0/en/Entera-Bio-Presents-Positive-New-Clinical-Data-from-EB613-Phase-2-Trial-Demonstrating-Significant-Bone-Density-Improvements-in-Early-Postmenopausal-Women.html
0 · Reply
DARKP00L
DARKP00L Oct. 23 at 1:15 PM
$ENTX 08:58 on Oct. 23 2025 Entera Bio Releases New Phase 2 Data At NAMS 2025 Showing That EB613, An Oral PTH[1-34] Therapy, Consistently Increased Bone Mineral Density In Both Early Postmenopausal Women And Those 10 Years Post-Menopause #tradeideas
0 · Reply
PennySpot
PennySpot Oct. 23 at 1:09 PM
ALERT ENTX · Score 95.2% | News: Entera Bio Releases New Phase 2 Data At NAMS 2025 Showing That EB613, An Oral PTH[1-34] Therapy, Consistently Increased Bone Mineral Density In Both Early Postmenopausal Women And Those 10 Years Post-Menopause --- https://news-static.webullfintech.com/us/news-html/20251023/13730920608436224.html | $2025-10-23 13:09:24 $$ENTX
0 · Reply
MHM7700
MHM7700 Oct. 23 at 12:58 PM
42% win on traded capital in less than 30 minutes on $ENTX, $MAIA and $INBS. That means if you invested 1,000 this morning, you would be walking off with more than 400 now as these trades were apart in time and you could use the same capital again and again. This is what we do everyday in our discord. This is what you get when you trade with real traders instead of FURUs here who just talk. I give clear trade alerts with PTs and SLs every time along with proof of me taking the same trade.
2 · Reply
MHM7700
MHM7700 Oct. 23 at 12:55 PM
13% win on the $ENTX trade. my covers were 50% @ 2.60 and 50% @ 2.50 from 2.89 short entry. https://stocktwits.com/MHM7700/message/633399722
0 · Reply
MHM7700
MHM7700 Oct. 23 at 12:54 PM
$ENTX short @ 2.89 PT @ 2.60 - 2.50 SL @ 3.00
0 · Reply
WallStWireAds
WallStWireAds Oct. 23 at 12:53 PM
$ENTX https://caplynx.io/GIsnrFm
0 · Reply
Stock_Catcher
Stock_Catcher Oct. 23 at 12:51 PM
$ENTX Entera Bio Presents Positive New Clinical Data from EB613 Phase 2 Trial Demonstrating Significant Bone Density Improvements in Early Postmenopausal Women
0 · Reply
OpenOutcrier
OpenOutcrier Oct. 23 at 12:51 PM
$ENTX (+17.4% pre) Entera Bio reports bone density gains in early menopause trial https://ooc.bz/l/81595
0 · Reply
Gsgsghshh
Gsgsghshh Oct. 22 at 9:36 AM
$ENTX do they have news today or I am mistaken?
1 · Reply
WallStWireAds
WallStWireAds Oct. 20 at 11:10 AM
$ENTX https://thefinanceherald.com/big-pharma-just-put-peptides-back-on-the-map-which-players-are-still-under-the-radar/
0 · Reply
DARKP00L
DARKP00L Oct. 16 at 1:11 PM
$ENTX 08:47 on Oct. 16 2025 Entera Bio Announces It Will Present New Phase 2 Clinical Data For EB613 At The North American Menopause Society 2025 Annual Meeting, October 21–25, 2025, In Orlando, Florida. #tradeideas
0 · Reply